RNAi-based nanomedicines for targeted personalized therapy

Ala Daka; Dan Peer

doi:10.1016/j.addr.2012.08.014

RNAi-based nanomedicines for targeted personalized therapy

Ala Daka, Dan Peer

Research output: Contribution to journal › Review article › peer-review

148 Scopus citations

Abstract

RNA interference (RNAi) has just made it through the pipeline to clinical trials. However, in order for RNAi to serve as an ideal personalized therapeutics and be clinically approved-safe, specific, and potent strategies must be devised for efficient delivery of RNAi payloads to specific cell types, which despite the immense potential, remains a challenge. Through evaluating the recent reported studies in this field, we introduce the progress in designing targeted nano-scaled strategies that are anticipated to overcome the delivery drawbacks and along with the exciting "omics" discipline to personalize RNAi-based therapeutics.

Original language	English (US)
Pages (from-to)	1508-1521
Number of pages	14
Journal	Advanced Drug Delivery Reviews
Volume	64
Issue number	13
DOIs	https://doi.org/10.1016/j.addr.2012.08.014
State	Published - Oct 2012

Keywords

ApoB
BD
Clinical trials
CME
CNT
DC-6-14
DOPE
DOTAP
DOTMA
DsRNA
EPR
I.V.
In vivo
MAb
MiRNA
MPS
MW
Nanoparticles
NP
Nt
P.I.
PC
PEG
PEI
Personalized medicine
PK
RES
RISC
RNA
Short interfering RNA (siRNA)
ShRNA
SNALP
Systemic delivery
T
TLR

ASJC Scopus subject areas

Pharmaceutical Science

Access to Document

10.1016/j.addr.2012.08.014

Cite this

@article{c30859a7e26d4634ad82461297b3567f,

title = "RNAi-based nanomedicines for targeted personalized therapy",

abstract = "RNA interference (RNAi) has just made it through the pipeline to clinical trials. However, in order for RNAi to serve as an ideal personalized therapeutics and be clinically approved-safe, specific, and potent strategies must be devised for efficient delivery of RNAi payloads to specific cell types, which despite the immense potential, remains a challenge. Through evaluating the recent reported studies in this field, we introduce the progress in designing targeted nano-scaled strategies that are anticipated to overcome the delivery drawbacks and along with the exciting {"}omics{"} discipline to personalize RNAi-based therapeutics.",

keywords = "ApoB, BD, Clinical trials, CME, CNT, DC-6-14, DOPE, DOTAP, DOTMA, DsRNA, EPR, I.V., In vivo, MAb, MiRNA, MPS, MW, Nanoparticles, NP, Nt, P.I., PC, PEG, PEI, Personalized medicine, PK, RES, RISC, RNA, Short interfering RNA (siRNA), ShRNA, SNALP, Systemic delivery, T, TLR",

author = "Ala Daka and Dan Peer",

note = "Funding Information: This work was supported in part by grants from the Marie Curie IRG-FP7 of the European Union, Lewis Family Trust, Israel Science Foundation (award no. 181/10 ), the Kenneth Rainin Foundation , the I-CORE Program of the Planning and Budgeting Committee and The Israel Science Foundation (grant no. 41/11 ) and the FTA: Nanomedicines for Personalized Theranostics of the Israeli National Nanotechnology Initiative to D.P. Copyright: Copyright 2013 Elsevier B.V., All rights reserved.",

year = "2012",

month = oct,

doi = "10.1016/j.addr.2012.08.014",

language = "English (US)",

volume = "64",

pages = "1508--1521",

journal = "Advanced Drug Delivery Reviews",

issn = "0169-409X",

publisher = "Elsevier",

number = "13",

}

TY - JOUR

T1 - RNAi-based nanomedicines for targeted personalized therapy

AU - Daka, Ala

AU - Peer, Dan

N1 - Funding Information: This work was supported in part by grants from the Marie Curie IRG-FP7 of the European Union, Lewis Family Trust, Israel Science Foundation (award no. 181/10 ), the Kenneth Rainin Foundation , the I-CORE Program of the Planning and Budgeting Committee and The Israel Science Foundation (grant no. 41/11 ) and the FTA: Nanomedicines for Personalized Theranostics of the Israeli National Nanotechnology Initiative to D.P. Copyright: Copyright 2013 Elsevier B.V., All rights reserved.

PY - 2012/10

Y1 - 2012/10

N2 - RNA interference (RNAi) has just made it through the pipeline to clinical trials. However, in order for RNAi to serve as an ideal personalized therapeutics and be clinically approved-safe, specific, and potent strategies must be devised for efficient delivery of RNAi payloads to specific cell types, which despite the immense potential, remains a challenge. Through evaluating the recent reported studies in this field, we introduce the progress in designing targeted nano-scaled strategies that are anticipated to overcome the delivery drawbacks and along with the exciting "omics" discipline to personalize RNAi-based therapeutics.

AB - RNA interference (RNAi) has just made it through the pipeline to clinical trials. However, in order for RNAi to serve as an ideal personalized therapeutics and be clinically approved-safe, specific, and potent strategies must be devised for efficient delivery of RNAi payloads to specific cell types, which despite the immense potential, remains a challenge. Through evaluating the recent reported studies in this field, we introduce the progress in designing targeted nano-scaled strategies that are anticipated to overcome the delivery drawbacks and along with the exciting "omics" discipline to personalize RNAi-based therapeutics.

KW - ApoB

KW - BD

KW - Clinical trials

KW - CME

KW - CNT

KW - DC-6-14

KW - DOPE

KW - DOTAP

KW - DOTMA

KW - DsRNA

KW - EPR

KW - I.V.

KW - In vivo

KW - MAb

KW - MiRNA

KW - MPS

KW - MW

KW - Nanoparticles

KW - NP

KW - Nt

KW - P.I.

KW - PC

KW - PEG

KW - PEI

KW - Personalized medicine

KW - PK

KW - RES

KW - RISC

KW - RNA

KW - Short interfering RNA (siRNA)

KW - ShRNA

KW - SNALP

KW - Systemic delivery

KW - T

KW - TLR

UR - http://www.scopus.com/inward/record.url?scp=84867642276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867642276&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2012.08.014

DO - 10.1016/j.addr.2012.08.014

M3 - Review article

C2 - 22975009

AN - SCOPUS:84867642276

SN - 0169-409X

VL - 64

SP - 1508

EP - 1521

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

IS - 13

ER -

RNAi-based nanomedicines for targeted personalized therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this